SCHEMBL5015686

SCHEMBL5015686

COc1cccc(C2=NOC3(CCN(C(=O)C4c5ccccc5Oc5ccccc54)CC3)C2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
HTT P42858 3/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 2/20 0.49
TSHR P16473 5/20 0.47
LMNA P02545 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPK1 P28482 1/20 0.47
TP53 P04637 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
TDP1 Q9NUW8 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 1/20 0.41
APAF1 O14727 1/20 0.41
KMT2A Q03164 1/20 0.41
NPY5R Q15761 1/20 0.40
POLB P06746 1/20 0.39
APEX1 P27695 1/20 0.39
RECQL P46063 1/20 0.39
MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5014536 0.91 NPC1 (0.51) ALDH1A1HTTNPC1RAB9ATSHR
SCHEMBL5129518 0.88 TSHR (0.53) ALDH1A1HTTTSHRLMNAKDM4E
SCHEMBL5015754 0.85 HTT (0.49) ALDH1A1HTTNPC1RAB9ATSHR
SCHEMBL15855842 0.81 NPC1 (0.51) ALDH1A1HTTNPC1RAB9ATSHR
SCHEMBL5012919 0.77 NPC1 (0.46) ALDH1A1HTTNPC1RAB9ATSHR
SCHEMBL5015805 0.77 NPC1 (0.46) ALDH1A1HTTNPC1RAB9ATSHR
SCHEMBL5121286 0.77 SMN1; SMN2 (0.55) ALDH1A1HTTNPC1RAB9ATSHR
SCHEMBL5015782 0.77 NPC1 (0.45) ALDH1A1HTTNPC1RAB9ATSHR
SCHEMBL5124433 0.76 SMN1; SMN2 (0.61) ALDH1A1HTTNPC1RAB9ATSHR
SCHEMBL5120699 0.76 HTT (0.38) ALDH1A1HTTNPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772307-B2 Substituted spiro compounds and their use for producing pain-relief medicaments GRUENENTHAL GMBH (DE) 2014-07-08 US claimed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 US claimed
EP-1888596-A1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS Grünenthal GmbH (DE) 2008-02-20 EP claimed
WO-2006122770-A1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS Grünenthal GmbH (DE) 2006-11-23 WO claimed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders INA, SCN1A, SI ALDH1A1 511/4885HTT 50/4885NPC1 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.